Advertisement

Lectin-binding analysis of serum alpha-fetoprotein: Predictive importance of the change of AFP sugar chain in the development of hepatocellular carcinoma

  • Yasuo Endo

Abstract

In Japan, hepatocellular carcinoma (HCC) usually develops on the basis of liver cirrhosis that results from chronic infection by hepatitis virus B (HVB) or C (HVC). One of the most important factors which influences the prognosis of the patient is early detection of the tumor, i.e., detection when it is as small as possible. HCC is diagnosed using a combination of imaging methods, such as ultrasound (US) techniques, computed tomography (CT), angiography, and tumor marker assays. Of the various tumor markers, alpha-fetoprotein (AFP) and protein induced by vitamin K antagonist II (PIVKA-II) are the most reliable, and for an early diagnosis of HCC, it is necessary to regularly check the patient using imaging methods and AFP assays. Because of recent progress in the development of diagnostic techniques, detection of tumors less than 2 cm in diameter is increasing. In patients with small tumors, 64% do not show elevation of serum AFP levels [1] (Table 1). However, in some patients, regular AFP checks give clues for the early detection of HCC.

Keywords

Chronic Hepatitis Liver Cirrhosis Ascites Fluid Sugar Chain Metastatic Liver Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Liver Cancer Study Group of Japan (1990) Primary liver cancer in Japan: Clinicopathologic features and results of surgical treatment. Ann Surg 211: 277Google Scholar
  2. 2.
    Abelev Gì, et al. (1963) Production of embryonal alpha-globulin by transplantable mouse hepatoma. Transplantation 1: 174–180PubMedCrossRefGoogle Scholar
  3. 3.
    Tatarinov YS (1964) Presence of embryonal alphaglobulin in the serum of patient with primary hepatocellular carcinoma (in Russian). Vopr Med Khim 10: 90–91PubMedGoogle Scholar
  4. 4.
    Morinaga T, et al. (1983) Primary structures of human alpha-fetoprotein and its mRNA. Proc Natl Acad Sci USA 80: 4604–4608PubMedCrossRefGoogle Scholar
  5. 5.
    Yoshima H, et al. (1980) Structures of the asparagine-linked sugar chains of alpha-fetoprotein purified from human ascites fluid. Cancer Res 40: 4279–4281Google Scholar
  6. 6.
    Yamashita K, et al. (1983) Sugar chain of alphafetoprotein produced in human yolk sac tumor. Cancer Res 43: 4691–4695PubMedGoogle Scholar
  7. 7.
    Purves LR, et al. (1970) Variants of alphafetoprotein. Lancet 11: 464–465CrossRefGoogle Scholar
  8. 8.
    Kortright KH, et al. (1978) Purification and physical characterization of human alpha-fetoprotein from cord blood and from ascites fluid of individuals with hepatocellular carcinoma. Scand J Immunol 8 (suppl 8): 347–360CrossRefGoogle Scholar
  9. 9.
    Alpert E, et al. (1972) Human alpha-fetoprotein. Isolation, characterization, and demonstration of microheterogeneity. J Biol Chem 247: 3792–3798PubMedGoogle Scholar
  10. 10.
    Smith CJ, et al. (1973) Alpha-Fetoprotein: separation of two molecular variants by affinity chromatography with concanavalin A-agarose. Biochem Biophys Acta 317: 231–235PubMedGoogle Scholar
  11. 11.
    Ruoslahti E, et al. (1978) Developmental changes in carbohydrate moiety of human alpha-fetoprotein. Int J Cancer 22: 515–520PubMedCrossRefGoogle Scholar
  12. 12.
    Miyazaki J, et al. (1981) Lectin affinities of alphafetoprotein in liver cirrhosis, hepatocellular carcinoma, and metastatic liver tumor (in Japanese). Acta Hepatol Jpn 22: 1559–1568CrossRefGoogle Scholar
  13. 13.
    Breborowicz J, et al. (1981) Microheterogeneity of alpha-fetoprotein in patient serum as demonstrated by lectin affino-electrophoresis. Scand J Immunol 14: 15–20PubMedCrossRefGoogle Scholar
  14. 14.
    Buamah PK, et al. (1986) Lentil-lectin-reactive alpha-fetoprotein in the differential diagnosis of benign and malignant liver disease. Clin Chem 32: 2083–2084PubMedGoogle Scholar
  15. 15.
    Taketa K, et al. (1985) Increased asialo-alphafetoprotein in patients with alpha-fetoprotein-producing tumors: Demonstration by affinity electrophoresis with erythroagglutinating phytohemagglutinin of Phaseolus vulgaris lectin. Tumor Biology 6: 533–544PubMedGoogle Scholar
  16. 16.
    Taketa K, et al. (1985) Antibody-affinity blotting, a sensitive technique for the detection of alphafetoprotein separated by lectin affinity electrophoresis in agarose gels. Electrophoresis 6: 492–497CrossRefGoogle Scholar
  17. 17.
    Aoyagi Y, et al. (1988) The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma. Cancer 61: 769–774PubMedCrossRefGoogle Scholar
  18. 18.
    Endo Y, et al. (1984) Lectin-affinity analysis of alpha-fetoprotein in liver diseases and in infantile diseases (in Japanese). Seibutsu butsuri kagaku 28: 355–360Google Scholar
  19. 19.
    Taketa K, et al. (1990) Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology 99: 508–518PubMedGoogle Scholar
  20. 20.
    Endo Y, et al. (1991) Analysis of patients with high risk of hepatocellular carcinoma by lectin binding technique of AFP (in Japanese). Seibutsu butsuri kagaku 35: 205–208CrossRefGoogle Scholar
  21. 21.
    Tsuji T, Osawa T (1983) Lectins and their sugar binding specificity (in Japanese) Tanpakushitsu Kakusa Koso 28: 118–131Google Scholar

Copyright information

© Springer-Verlag Tokyo 1992

Authors and Affiliations

  • Yasuo Endo
    • 1
  1. 1.Sanraku HospitalChiyoda-ku, TokyoJapan

Personalised recommendations